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Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione], a polyphenolic
compound isolated from the rhizomes of Curcuma longa (turmeric), has been shown
to exhibit a wide range of pharmacological activities including anti-inflammatory,
anti-cancer, anti-oxidant, anti-atherosclerotic, anti-microbial, and wound healing effects.
These activities of curcumin are based on its complex molecular structure and chemical
features, as well as its ability to interact with multiple signaling molecules. The ability of
curcumin to regulate ion channels and transporters was recognized a decade ago. The
cystic fibrosis transmembrane conductance regulator (CFTR) is a well-studied ion channel
target of curcumin. During the process of studying its anti-cancer properties, curcumin
was found to inhibit ATP-binding cassette (ABC) family members including ABCA1,
ABCB1, ABCC1, and ABCG2. Recent studies have revealed that many channels and
transporters are modulated by curcumin, such as voltage-gated potassium (Kv) channels,
high-voltage-gated Ca2+ channels (HVGCC), volume-regulated anion channel (VRAC), Ca2+
release-activated Ca2+ channel (CRAC), aquaporin-4 (AQP-4), glucose transporters, etc., In
this review, we aim to provide an overview of the interactions of curcumin with different
types of ion channels and transporters and to help better understand and integrate the
underlying molecular mechanisms of the multiple pharmacological activities of curcumin.
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INTRODUCTION
Turmeric, the rhizome of Curcuma longa L. has been used since
ancient times as a spice, coloring, flavoring, and traditional
medicine. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione], an important active agent of turmeric,
has been shown to exhibit a wide range of pharmacological
activities including anti-inflammatory, anti-cancer, anti-oxidant,
anti-atherosclerotic, anti-microbial, and wound healing effects
(Maheshwari et al., 2006). These activities of curcumin are based
on its chemical features, as well as its ability to interact with
multiple signaling molecules. Many biological molecules have
been identified as targets of curcumin, including transcription
factors, growth factors, inflammatory cytokines, protein kinases
and other enzymes (Zhou et al., 2011). The safety, tolerabil-
ity, and non-toxicity of curcumin at high doses have been well
established in many clinical trials. Different phase I clinical trials
indicated that curcumin is well tolerated when taken in dose as
high as 12 g per day. However, curcumin exhibits poor bioavail-
ability at the same time (Anand et al., 2007). Thus, numerous
approaches have been undertaken to improve its bioavailability,
including the use of piperine, nanoparticles, liposomes, phos-
pholipid complexes, and structural analogues (Gupta et al.,
2013).
Studies have shown that curcumin influences a variety of
ion channels and transporters across several signaling path-
ways, ranging from the well-studied CFTR to recently identified
hERG potassium channel. The list is continuously expanding
and it would not be surprising to find novel molecules in the
future. Here, we summarized the known effects of curcumin on
ion channels and transporters to help better understanding the
underlying molecular mechanisms of multiple pharmacological
activities of curcumin.
EFFECTS OF CURCUMIN ON ION CHANNELS
POTASSIUM CHANNELS
Kv channels play important roles in regulating resting membrane
potential. It has long been observed that cells possessing a high
degree of polarization tend to be quiescent (Wonderlin and
Strobl, 1996; Sundelacruz et al., 2009). As a potent blockage of
Kv channels, curcumin reduces the Kv current in rabbit coronary
arterial smooth muscle cells (Hong Da et al., 2013) and Jurkat T
cells (Shin et al., 2011), inhibits Kv1.3 in effector memory T cells
(TEM) (Lian et al., 2013), and blocks Kv11.1 potassium current in
human monocytic leukemia (AML) cell lines THP-1 (Banderali
et al., 2011) and HEK293 (Choi et al., 2013). Curcumin pre-
vents Kv channel from activating, which consequently suppresses
proliferation of AML cells and TEM cells, whereby exerts its anti-
cancer or anti-inflammatory effects (Banderali et al., 2011; Lian
et al., 2013). However, the mechanisms underlying the inhibitory
effects of curcumin are not fully understood. Several studies sug-
gest that curcumin inhibits Kv current via direct action on the Kv
channels (Choi et al., 2013; HongDa et al., 2013; Lian et al., 2013),
possibly through its interaction with the pore blocker binding site
(Choi et al., 2013).
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Curcumin is also an effective antinociceptive agent. Studies
suggest that activation of KATP channels, possibly by direct
stimulation, contributes to the antinociceptive effect of curcumin
(De Paz-Campos et al., 2012). Additional potential mechanisms
of the antinociceptive effect of curcumin include activating Gi/o
proteins, stimulating the particular form of guanylyl cyclase or
acting through the hydrogen sulfide-KATP channel pathway.
Since the direct evidence is still lacking, further study is needed
to fully reveal this mechanism. Curcumin has also been shown
to inhibit intermediate-conductance Ca2+-activated K+ channel
(SK4) (Shin et al., 2012), but relevant physiological study is still
elusive.
On the other hand, curcumin has been shown to open K+
channel. In goat ruminal artery, curcumin induces vasorelaxation
by, at least in part, directly activating soluble guanylate cyclase
(sGC) mediated cGMP pathway followed by the opening of K+
ion channel (Dash and Parija, 2013). Given the diverse regula-
tory effects of curcumin on multiple targets, it is not surprising
that curcumin may participate in different pathways and lead to
different physiological actions of K+ channels.
CALCIUM CHANNELS
The increase of the intracellular Ca2+ concentration is widely
viewed as the most important contributor to neurodegenera-
tion and neuronal cell death (Duncan et al., 2010). Calcium
channel blockade is one approach among the neuroprotective
strategies (Singer, 2012). Curcumin has been demonstrated to
reversibly inhibit HVGCC currents via a novel protein kinase
C-θ-dependent pathway, which could contribute to its neuro-
protective effects in rat hippocampal neurons (Liu et al., 2013).
In another study, it has been shown that curcumin inhibits
glutamate release from rat prefrontocortical synaptosomes by
suppressing presynaptic voltage-gated calcium channels Cav2.2
and Cav2.1 (Lin et al., 2011). This effect of curcumin might
relate to the mechanisms underlying the antidepressant effect
of curcumin. Curcumin has also been observed to inhibit Ca2+
release-activated Ca2+ (CRAC) channels (Shin et al., 2011, 2012).
Calcium influx is mainly mediated by store-operated Ca2+
entry (SOCE) through CRAC channels located in the plasma
membrane, which is important for the activation and function of
all cells in the immune system (Shaw et al., 2012). The inhibition
of CRAC and another major ion channel Kv1.3 in lymphocytes
might contribute to the anti-inflammatory effect of curcumin.
The function of CRAC channels is primarily mediated by Orai
proteins, which are located in the plasma membrane as the Ca2+
conducting pore unit (Shaw et al., 2012). Curcumin contains elec-
trophilic α,β-unsaturated carbonyl groups that potentially form
Michael addition with cysteine residues. The electrophilic addi-
tion to the Orai1 195Cys is responsible for the inhibitory effect of
CRAC by curcumin (Choi et al., 2013).
CHLORIDE CHANNELS
CFTR acts as a Cl− channel on the apical membrane of epithe-
lia. Mutations in the CFTR gene cause the reduction of CFTR
expression or abnormalities in its function, thereby resulting in
cystic fibrosis (CF), a genetic disease. The most common CF-
causing mutation is F508-CFTR, which leads to CFTR protein
misfolding and retention in the endoplasmic reticulum (ER).
Wild type and mutant CFTR channels can be activated by cur-
cumin. Curcumin not only rescues F508-CFTR localization by
allowing F508-CFTR to escape from ER and to anchor in the
plasma membrane (Egan et al., 2004; Cartiera et al., 2010), but
also stimulates its channel activity once it reaches the plasma
membrane (Berger et al., 2005; Lipecka et al., 2006). This capac-
ity of curcumin to release F508-CFTR from the ER is likely due
to the dissolution of the calnexin-F508-CFTR complex and the
stabilization of the tertiary structure ofF508-CFTR (Egan et al.,
2004). Curcumin also potentiates another CFmutant channel, the
glycine-to-aspartate missense mutation at position 551 (G551D).
G551D-CFTR is the third most common CF-associated muta-
tion, which is characterized by an extremely low open probability
despite its normal trafficking to the plasma membrane (Miki
et al., 2010). Curcumin increases the activity of the G551D-CFTR
mutant channel (Yu et al., 2011). The cross-link of curcumin
and these two CF mutant channels could be prevented by high
concentrations of oxidant scavengers In Vitro, indicating a pos-
sible oxidation reaction of curcumin with the CFTR polypeptide
(Bernard et al., 2009).
However, some studies fail to reproduce these results. Song
et al. are unable to demonstrate the effectiveness of curcumin on
the functional correction of the defective F508-CFTR process-
ing in transfected cells, native airway cells, andmutantmice (Song
et al., 2004). Dragomir et al. have observed that curcumin causes a
small increase in net cAMP-activated chloride efflux fromF508-
CFTR expressing baby hamster kidney (BHK) cells, but fails to
show the significant movements of F508-CFTR to the plasma
membrane in F508-CFTR BHK cells (Dragomir et al., 2004).
Gao et al. have shown that curcumin does not change CFTR
expression level and forskolin-induced CFTR gating in Madin–
Darby canine kidney (MDCK) cell monolayer (Gao et al., 2011).
These contradictions may be due to different genetic backgrounds
of the animals studied, or different preparation of curcumin
extract, etc. (Mall and Kunzelmann, 2005). Thus, although cur-
cumin may be a desirable alternative for treating CF, its efficacy
needs to be carefully evaluated (Mall and Kunzelmann, 2005).
VRAC plays an important role in regulating electrical and
secretory activity in the β-cell. Curcumin activates VRAC, leading
to Cl− efflux in β-cells. A study using single channel recording
has indicated that this activation is the result of increased chan-
nel open probability (Gao et al., 2011). This study could partly
explain the hypoglycemic action of curcumin.
OTHER CHANNELS
AQP-4, the predominant isoform of water channels in the brain,
plays an important role in fluid generation, transfer, and absorp-
tion in brain. Curcumin attenuates the increase of AQP-4 expres-
sion induced by hypoxic–ischemic brain damage (HIBD) in the
hippocampus (Yu et al., 2012). Since blood-brain barrier opening
depends on the upregulation of AQP-4 function (Papadopoulos
and Verkman, 2007), this study suggests that by down-regulating
AQP-4, curcumin may protect astrocytic foot processes sur-
rounding brain capillaries from damaging from HIBD edema.
Curcumin could also block IL-1β-induced AQP-4 expression
in the cultured astrocytes and further reduce glial activation
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and cerebral edema following neurotrauma (Laird et al., 2010).
However, in lupus erythematosus, curcumin increases brain
AQP4 expression and water content (Foxley et al., 2013). Along
with other evidence, it seems that curcumin aggravates some CNS
disease manifestations in experimental lupus erythematosus.
Transient receptor potential (TRP) cation channel subfamily A
member 1 (TRPA1) is a nociceptor specific ion channel expressed
in a subset of TRPV1-expressing neurons. It has been an attractive
target for various therapeutical interventions in the disease con-
ditions, such as pain, asthma, and cough (Bandell et al., 2004).
Curcumin causes activation and subsequent desensitization of
native and recombinant TRPA1 ion channels of multiple mam-
malian species (Leamy et al., 2011). This effect may contribute to
the analgesic effect of curcumin in patients with various chronic
diseases (Di Pierro et al., 2013).
Curcumin is also a potent inhibitor of the inositol 1,4,5-
trisphosphate-sensitive Ca2+ channel (IP3 receptor). By inhibit-
ing IP3 receptor, curcumin stimulates Ca2+ uptake, reduces Ca2+
leakage and inhibits IP3-induced Ca2+ release (IICR) from ER
Ca2+ storage, blocks a multitude of subsequent Ca2+-dependent
cellular events. This inhibition is likely non-competitive in nature
(Dyer et al., 2002).
EFFECTS OF CURCUMIN ON TRANSPORTERS
ATP-BINDING CASSETTE (ABC) DRUG TRANSPORTER
ABC proteins are a large family of integral membrane pro-
teins. They, collectively, serve a wide variety of cellular functions.
ABC drug transporters actively transport a variety of amphi-
pathic compounds. The overexpression of ABC drug transporters
causes multidrug resistance (MDR) in cancer cells. Among ABC
transporter family, three of them, ABCB1 (P-glycoprotein/Pgp),
ABCC1 (multidrug resistance protein 1/MRP1) and ABCG2
(breast cancer resistance protein /MXR/BCRP) appear to play
an important role in the development of MDR in cancer cells
(Wu et al., 2008; Orina et al., 2009). Curcumin has been studied
as a potential anticancer drug for many years, not only because
of its antiproliferative or apoptosis-inducing effect on several
cancer cells, but also due to its ability to reverse MDR pheno-
types in several cancer cells overexpressing ABC transporters,
such as, ABCB1, ABCC1, and ABCG2 (Sharma et al., 2009).
Curcuminoids (including curcumin, demethoxycurcumin and
bisdemethoxycurcumin) sensitizes the ABCG2-expressing cells
to conventional chemotherapeutic agent mitoxantrone, topote-
can, SN-38, and doxorubicin. The reversal of resistance is due
to their influence on the function rather than the protein lev-
els of ABCG2 (Chearwae et al., 2006). Curcumin also inhibits
ABCG2-mediated efflux of sulfasalazine and increases the area
under the curve (AUC) of plasma sulphasalazine both in vivo
(Shukla et al., 2009) and in vitro (Kusuhara et al., 2012). In the
case of ABCB1 (Pgp), its overexpression on the surface of tumor
cells is often linked to MDR. In the multidrug-resistant human
cervical carcinoma cell line KB-V1, curcumin is able to signifi-
cantly lower the Pgp expression and reduce the function of Pgp.
Curcumin is not a substrate for Pgp, but it interacts directly with
drug binding site of the transporter (Anuchapreeda et al., 2002;
Limtrakul et al., 2007). Treatment of KB-V1 cells with curcumin
increases their sensitivity to vinblastine (Anuchapreeda et al.,
2002; Limtrakul et al., 2007). In MCF-7/ADR cells overexpressing
Pgp, curcumin significantly enhances the cellular accumulation of
rhodamine-123 in a concentration-dependent manner, indicat-
ing that curcumin significantly inhibits Pgp activity (Cho et al.,
2012). This evidence suggests that curcumin could be an effec-
tive MDR modulator, and may be used in combination with
conventional chemotherapeutic drugs to reverse MDR in cancer
cells.
Needless to say, the trafficking of curcumin depends on trans-
porters as well. Curcumin-resistance has also been observed in
some cancer cells, and efflux of curcumin by ABC transporters is
considered as one of the factors causing resistance. In hypoxia-
induced curcumin-resistance in HepG2 cells, the expression of
ABC drug transporter genes, including ABCC1, ABCC2, and
ABCC3, are increased by more than two-fold. Both inhibitors
of ABCC1/ABCC2 are able to reverse this curcumin resistance
(Sakulterdkiat et al., 2012). In resistant M14 melanoma cells, the
ABCA1 is over-expressed as compared to that in the curcumin-
sensitive MDA-MB-231 breast cancer cells. Gene silencing of
ABCA1 sensitizes M14 cells to the apoptotic effect of curcumin
(Bachmeier et al., 2009). Therefore, the expression level of the
involved ABC drug transporters should be monitored as poten-
tial response predictors in curcumin treatment for certain types
of cancer.
ABC molecules, especially ABCA and ABCG subfamily mem-
bers, are critical in the regulation of lipid-trafficking as well
(Schmitz et al., 2001), through which curcumin affects lipid
metabolism, contributing its beneficial effects on inflammation,
cardiovascular diseases and obesity. In macrophages, treatment
with curcumin markedly ameliorates cholesterol accumulation
by increasing cholesterol efflux, due to up-regulation of ABCA1.
Curcumin administration modulates the expression of ABCA1
and ABCG1 in apoE−/− mice (Zhao et al., 2012). Curcumin also
increases the cholesterol efflux from adipocytes. The increased
expressions of PPARγ, LXRα and ABCA1 induced by curcumin
are parallel and correlated, suggesting that curcumin can affect
the cholesterol efflux from adipocytes by regulating the PPARγ-
LXR-ABCA1 pathway (Dong et al., 2011).
GLUCOSE TRANSPORTER (GLUT)
One of the merits for curcumin used as an anti-diabetic medi-
cation is its ability to lower blood glucose likely by interacting
with GLUT. Evidence suggests curcumin influences subtypes of
GLUT. Hyperglycemia stimulates hepatic stellate cell (HSC) acti-
vation in vitro by increasing intracellular glucose. Curcumin
eliminates this stimulatory effect via blocking the membrane
translocation of GLUT2 and suppressing GLUT2 expression. The
former effect is mediated by interrupting the p38 MAPK signal-
ing pathway and the latter by activating PPARγ and attenuating
oxidative stress (Lin and Chen, 2011). In the leptin-induced
HSC activation, curcumin suppresses the membrane transloca-
tion of GLUT4 by interrupting the insulin receptor substrates
(IRS)/PI3K/AKT signaling pathway (Tang and Chen, 2010). On
the other hand, Cheng et al. have shown that curcumin causes
a concentration-dependent increase of glucose uptake by skeletal
muscle cells isolated fromWistar rats, and this action is mediated
by increasing membrane protein level of GLUT4 (Cheng et al.,
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2009). The increased GLUT4 is reversed by blocking muscarinic
M-1 cholinoceptor (M1-mAChR) or PLC/PI3K pathway. These
phenomena suggest that the effects of curcumin on GLUT are
complicated and may be tissue specific and/or signaling pathway-
dependent.
OTHER TRANSPORTERS
Glutamate facilitates the pathogenesis of post-ischemic neu-
ronal injury. Glutamate transporter-1 (GLT-1) is essential for
maintaining a low extracellular glutamate concentration and for
preventing glutamate neurotoxcity. Curcumin may reduce cere-
bral vasospasm (CVS) and neurologic injury via an antioxidant
effect and attenuate glutamate-induced neurotoxicity. In a sub-
arachnoid hemorrhage (SAH)-induced rat CVSmodel, glutamate
levels are lower in the curcumin treated group vs. the saline and
vehicle treated groups. Correspondingly, GLT-1 is preserved after
SAH in curcumin-treated rats (Kuo et al., 2011). These results
suggest that curcumin may modulate GLT-1.
Curcumin increases the expression of two lipid transport
genes, the fatty acids transporter CD36/FAT and the fatty acids
binding protein 4 (FABP4/aP2) in THP-1 and RAW264.7 mono-
cytes and macrophages, leading to increased lipid levels in THP-1
and RAW264.7 (Zingg et al., 2012), though the significance of
the findings on the effect of curcumin against oxidant and lipid-
induced damage needs to be further studied.
Intestinal Niemann-Pick C1-like 1 (NPC1L1) cholesterol
transporter plays an essential role in the maintenance of choles-
terol homeostasis. Curcumin exhibits effects of lowering plasma
cholesterol and preventing diet-induced hypercholesterolemia.
Treating Caco-2 cell monolayers with curcumin significantly
inhibits cholesterol esterification and uptake. Coincidentally, the
NPC1L1 mRNA level and protein expression are significantly
decreased (Feng et al., 2010; Kumar et al., 2011). This evidence
suggests that hypocholesterolemic effect of curcumin may be
linked to the suppression of NPC1L1 expression in the intestinal
cells.
MECHANISMS UNDERLYING REGULATORY EFFECTS OF CURCUMIN
Although it has been under intensive investigations and scientific
debates, the detailed mechanisms underlying the diverse effects
of curcumin remain elusive. One argument is that curcumin is a
modulator of membrane structure; it may affect the membrane
proteins in a non-specific way. Ingolfsson et al. explored whether
curcumin modifies general lipid bilayer properties using chan-
nels formed by gramicidin A (gA). They found that curcumin
decreases the stiffness of the lipid-bilayer and increases the life-
times and appearance rates of gA channel, suggesting that the
energetic cost of the gA-induced bilayer deformation is reduced
(Ingolfsson et al., 2007). Another study showed that curcumin
affects membrane structure in a manner analogous to lipophillic
drugs, which are inserted deeply into the membrane in a trans-
bilayer orientation and anchored by hydrogen bonding to the
phosphate group of lipids (Barry et al., 2009). Other studies,
however, demonstrated that curcumin possesses a specific prop-
erty or mechanism underlying its modulation of the transporters
or channels. In a case of CFTR regulation, curcumin is able to
cross-link CFTR polypeptides and phosphorylate the R domain
of CFTR channel (Bernard et al., 2009). For the hERG potassium
channel, curcumin exerts the pore-blocking effect (Choi et al.,
2013). The effect of curcumin on TRPV1 channel is dependent
on disease conditions. Curcumin exerts no effects on the TRPV1
channel in normal tissue, whereas activates TRPV1 channel in
colitis (Martelli et al., 2007). These studies suggest that cur-
cumin exhibits its unique effects on ion channels and transporters
through different mechanisms far beyond a non-specific effect
although some of curcumin’s effectiveness may be membrane-
mediated. The exact mechanisms on each particular channel and
transporter need to be further elucidated.
CONCLUSION
These studies have provided ample evidence that curcumin affects
a variety of ion channels and transporters, and hence modulates
various critical physiological functions. In many circumstances,
regulatory effects of curcumin may be presented with a multi-
faceted nature given the multiple targets and different pathways
in which curcumin is involved. Despite there being several clini-
cal trials involving curcumin, no clear clinical indication has been
yet defined. More studies are needed to fully evaluate the efficacy
of curcumin in its utility as a therapeutic agent for the different
diseases. Nevertheless, given its potential multiple targets, phar-
macological safety and enhanced bioavailability, curcumin is a
promising natural product that is likely to be brought to the fore-
front of therapeutic agents for treatment of human diseases in the
future.
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